Follow-Up Schedule for Patients with Impaired Renal Function After Treatment Initiation

Initial Post-Treatment Assessment

• The American College of Cardiology recommends laboratory and clinical evaluation within 3 days (and no later than 7 days) after the last RRT session for patients recovering from dialysis-dependent AKI, followed by regular and frequent assessments 1, 2, 3
• Recovery from RRT dependence is defined as sustained independence from dialysis for a minimum of 14 days, and close follow-up after hospital discharge ensures that independence from RRT is truly sustained 1, 2, 3
• Continued nephrologist follow-up is recommended for all patients recovering from AKI 1, 2, 3

Medication-Specific Monitoring Protocols

• The American Heart Association recommends checking renal function and electrolytes 2-4 weeks after initiating ACE inhibitors, ARBs, or diuretics 4
• The American College of Cardiology recommends more intensive monitoring for aldosterone antagonists, with assessments within 2-3 days, at 7 days, and at least monthly for the first 3 months after initiation 5, 6
• The Scottish Intercollegiate Guidelines Network recommends checking renal function at 1 week, then at 2, 3, 4, and 6 months, then 6-monthly thereafter if stable for patients on aldosterone antagonists 7

Risk-Stratified Approach

• The European Society of Cardiology notes that patients with congestive heart failure, cirrhosis, malignancy, or more severe baseline renal impairment require earlier or more frequent monitoring 3

Long-Term Follow-Up Strategy

• The American Urological Association recommends annual follow-up for stable patients on chronic therapy, with reassessment of symptoms, complications, and treatment adjustments 8, 9
• The American College of Cardiology recommends follow-up intervals of 3-6 months for stage 1 hypertension with <10% 10-year ASCVD risk, 1 month for stage 1 hypertension with ≥10% 10-year ASCVD risk, and 1 month for stage 2 hypertension 4

Special Considerations for Medication Adjustment

• The National Institute for Health and Care Excellence recommends adjusting renally excreted medications at each follow-up visit, avoiding or withdrawing nephrotoxic medications and drugs with active metabolites 1, 2, 3
• The Kidney Disease: Improving Global Outcomes guidelines recommend considering alternative markers like cystatin C or direct GFR measurement in selected cases, especially when assessing kidney function in patients who received RRT 1, 2